title: [Following communications made at American Society of Clinical Oncology 2010, what will change our practice? The point of view of the editorial board of Bulletin du Cancer].
abstract: The congress of Asco made the object of numerous summaries of congress made in the heat of the moment and the Bulletin du Cancer decided to ask to his editorial board, a digested summary, at distance of the congress, to try to sum up the data of the congress which are going to change practice. Of the considerable number of communications, editorial board chose 40 communications which appeared to answer these rules. Best understanding of biological mechanisms and new molecules to inhibit targets allow in certain case, to use therapeutic targeting in the true sense. The identification of the gene of fusion EML4-ALK in lung adenocarcinoma, and its inhibition by the crizotinib, constitute a considerable progress for 5% of patients with this disease. Molecular biology with the mutations of the exon 11 in GIST, allow to better define the population which is going to benefit from adjuvant imatinib. In Advanced non-small cell lung cancer, myeloma and advanced lymphoma, maintenance therapy by monoclonal anti-body or inhibitors of tyrosines kinases showed the proof of their effectiveness. In advanced melanoma, ipilimumab is a light of hope in a pathology in always prognostic is so dark. In metastatic adenocarcinoma of the pancreas, there is finally an alternative to gemcitabine with the Folfirinox regimen, with an improvement of overall survival. Biological personalization of cancer treatments is on the road run but the road is still long.
authors.affiliation: Service d'hépatogastroentérologie, hôpital Pitié-Salpétrière, 47-83, boulevard de l'Hôpital, 75651 Paris cedex 13, France. thierry.andre@psl.aphp.fr
authors.forename: T
authors.initials: T
authors.lastname: André
authors.forename: M
authors.initials: M
authors.lastname: Wislez
authors.forename: A
authors.initials: A
authors.lastname: Goncalves
authors.forename: T
authors.initials: T
authors.lastname: de La Motte Rouge
authors.forename: J-Y
authors.initials: JY
authors.lastname: Blay
authors.forename: C
authors.initials: C
authors.lastname: Massard
authors.forename: J-O
authors.initials: JO
authors.lastname: Bay
mesh_terms: D001943:Breast Neoplasms / Q000628:therapy; D004067:Digestive System Neoplasms / Q000628:therapy; D005260:Female; D046152:Gastrointestinal Stromal Tumors / Q000188:drug therapy; D005833:Genital Neoplasms, Female / Q000188:drug therapy; D019337:Hematologic Neoplasms / Q000628:therapy; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy; D008297:Male; D008495:Medical Oncology / Q000592:standards*; D008545:Melanoma / Q000188:drug therapy; D009369:Neoplasms / Q000628:therapy*; D010818:Practice Patterns, Physicians' / Q000592:standards*; D011471:Prostatic Neoplasms / Q000188:drug therapy; D012509:Sarcoma / Q000188:drug therapy; D012955:Societies, Medical / Q000592:standards*; D013736:Testicular Neoplasms / Q000188:drug therapy; D013964:Thyroid Neoplasms / Q000188:drug therapy; D014481:United States